Our original intention is to continue to pursue the core competence of innovative science, combined with our Access to Medicines Strategy Program, so as to conduct the development of new drugs and will continue to promote “Accessibility”to new medicines for patients around the world, and meet the supply through legal and safe channels. Besides, set fair, reasonable and affordable prices to make patients “Affordability”, assist patients in economically disadvantaged countries to “Availability” new drugs, and reduce access disparities. We maximize patient coverage in global markets as much as possible to enhance patient health and well-being.

Performance highlights

Corresponding SDGs


Governance on Access to Medicine

Management Approach on Access to Medicine

Key Strategies and Actions on Access to Medicine


Globalizing Local Capacity Building and Access to Healthcare

Management Approach on Access to Healthcare

PharmaEssentia adheres to a patient-centered approach, and plans various actions and support programs to implement access to medicine and meet patients' health-related needs. Through activities such as health education, financial and medical support, academic exchanges and more, we provide patients with a comprehensive and integrated plan that covers every stage of their treatment. For patients already using BESREMi, a series of health promotion activities have been planned to extend their medication duration and improve overall treatment outcomes. By promoting local Healthcare and social participation to expand our external social influence.

Value Chain Empowerment Program

Intellectual Property Sharing Promotes Access to Medicine

PharmaEssentia attaches great importance to the transparency and sharing of intellectual property rights and take patent rights as the layout of business development strategy. we licensing-out patents and technologies from large foreign pharmaceutical strategic partners, licensing- in to introduce potential patents and technologies .We will establish a systematic management mechanism for licensing-out and licensing-in management based on our own patents and technologies, in order to maximize the management efficiency and social value of intellectual property rights. In the future, the Company promises to take into consideration the access to medicine of patients in least developed countries (LDCs) and low income countries (LICs) when utilizing and applying for patents to ensure the treatment needs of patients.

  • Intellectual Property Right Commitment
  • Patent and Trademark Management Policies and Performance
  • Technology Licensing can Maximize the Value of Intellectual Property
  • Short-to-Medium-Term Drug License Registration Plan
  • Global Marketing and Market Promotion

Tackling Medical Costs

Improving Product Medical Efficiency

Improving medical efficiency by providing innovative drugs that contribute to healthcare is a goal that PharmaEssentia strives to achieve. We have completed a comprehensive economic evaluation, including cost-effectiveness, cost-utility, and cost-benefit analysis, for BESREMi® upon its launch in Europe, to analyze the product's impact on medical costs. BESREMi® has achieved a coverage rate of 100% and has already been included in the ELN guidelines in 2021. As for the US market, BESREMi® is the first interferon approved by the US FDA for the treatment of PV, a rare blood disorder, and is eligible for orphan drug licenses. It has also been included in the NCCN guidelines for PV treatment. BESREMi® can be used as a suggested treatment for PV in adults, regardless of previous treatment or high-risk population status. The guidelines also include details on recommendations, providing comprehensive advice for medical practitioners on diagnosis, treatment, and patient management. We are actively collecting relevant data as the basis for future medical technology evaluations to certify the medical value of BESREMi®.

Fair and Reasonable Pricing

When pricing our drugs, patient interests are our top priority. We take into consideration various factors, such as the investment in research and development, the number of patients who would benefit from the treatment during the patent period, the pricing of competing products, expected profits, third-party insurance claims, and health insurance coverage provided by regulatory authorities. We then use these factors to determine a fair price, taking into account the ability of different countries to afford the medication, their level of economic development, and the cost of manufacturing the drug. We also refer to the WHO Guideline on Country Pharmaceutical Pricing Policiespublished by the World Health Organization to determine reasonable and fair drug prices.


Contributions Throughout a Patient's Treatment

PharmaEssentia not only stops at the development of new drugs but takes concrete action to improve patient care throughout their treatment.。


Ethical Pharmaceutical Marketing

Our company strictly adheres to all applicable industry regulations and stipulated provisions in marketing and sales, ensuring that all relevant personnel receive appropriate training and comply with ethical standards. In 2022, there were no violations of any marketing and communications-related regulations, and the company adhered to ethical pharmaceutical marketing practices.

Ethical Policies and Commitments for Drug Marketing


Annual implementation of Corporate Sustainable Development

               【Annual implementation of Corporate Sustainable Development _2023】

 Since 2016, we have been providing long-term sponsorship for the Asia Myeloproliferative Neoplasms International Conference (MPN Asia). To date, six successful conferences have been held, spanning four cities across Asia. These conferences have brought together top international experts, scholars, and clinical physicians to engage in profound interaction and academic exchange regarding the research and treatment of blood disorders.

  Continued support for the CHIA-YI MPN Center and the Taiwan Myeloproliferative Neoplasms Association (TMPNA) in providing services to patients with myeloproliferative neoplasms, implementing patient education and support activities in the Taiwan region. 

  Sponsoring the One Song’s New Year Concert for five consecutive years, supporting cultural and artistic development, and promoting a new ecosystem of inclusiveness and mutual benefit in response to UN SDGs 8 and 11. 

  Ongoing sponsorship of the Digital Humanitarian Association's Rural Health Promotion Philanthropy, supporting local health aging through digital technology-enabled remote medical care models, and actively caring for vulnerable groups in response to UN SDGs 3, 4, 5, 8, 10, 11, 13, and 17. 

  Sponsorship of the Jane Goodall Institute's Hope Box Biodiversity Public Welfare Project, contributing efforts to the protection and sustainable use of biodiversity for the benefit of human health. This aligns with UN SDGs 3, 4, 13, 15, the Convention on Biological Diversity (CBD), and the World Health Organization's (WHO) health advocacy. 

  The subsidiary, Panco, establishes the patient education interactive platform "MPN iCare ", providing educational information to patients and their families. In 2023, a total of 17 seminars were held to enhance the understanding of the disease and drug treatment choices for healthcare professionals, patients, and others, with a total participation of approximately 700+ people.  Assistance was also provided to TMPNA for organizing World MPN Day educational lectures and the first members' meeting. 

  The U.S. subsidiary initiated patient support activities through “BESREMi.com and the SOURCE program”, offering a comprehensive range of services including insurance support and the convergence of educational resources for patients. 

   The new drug Ropeginterferon alfa-2b (Ropeg) is listed as a treatment option for polycythemia vera (PV) in adults, and in May of 2023, it was upgraded to the preferred drug for PV_2A category patients in the United States NCCN Guidelines. 

  The company has applied the new product Ropeginterferon alfa-2b (P1101) in the Compassionate Use program since 2017, benefiting a total of 43 patients in 4 countries as of the end of 2023. 

  In July of 2023, the factory director of the Taichung plant was invited to speak at BIO Asia–Taiwan 2023, sharing insights on biotechnology technology exchange and trends, contributing to the learning and sharing of scientific and technological developments in the biotechnology field and enhancing the company's visibility.

  In August of 2023, the Director of Sustainability Center was invited to the DCB "Biomedical Product Industry Low Carbon Transformation Promotion Plan - Green Manufacturing Technology and Carbon Reduction Practice Symposium," sharing the company's journey and practical experiences in promoting sustainable development, contributing to collaboration and mutual growth in the biotechnology industry. 

  In October of 2023, the factory director of the Taichung plant was invited to share experience on GMP process change management and practices in the "Innovative Pharmaceutical Industry Chain International Competitiveness Enhancement Project," contributing to the continuous improvement of product quality and positive impact in compliance with regulatory requirements in the pharmaceutical industry.

Contribution to Access to Medicine

Our original intention is to continue to pursue the core competence of innovative science, combined with our Access to Medicines Strategy Program. By promoting local Healthcare and social participation, and linking Value Chain Empowerment Program to expand our external social influence. We also focus on Tackling Medical Costs so as to reduce access disparities and enhance patient health and well-being.

Downloads Contribution to Access to Medicine Report